- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523792
Virginia Opioid Treatment-Emergency Department (VOT-ED)
February 9, 2021 updated by: Virginia Commonwealth University
The current study seeks to test the feasibility of an alternative treatment for patients with opioid use disorder who present to the emergency department seeking treatment or with opioid withdrawal, which includes FDA approved long-acting medication for opioid misuse (SUBLOCADE) and rapid transfer of care to outpatient substance abuse treatment.
Study Overview
Detailed Description
This proof of concept study will provide feasibility data on whether rapid initiation of SUBLOCADE® (buprenorphine extended-release) injection for subcutaneous use CIII in the ED, Clinical Decision Unit, or inpatient unit and after administration of a test dose of SUBOXONE® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use CIII among treatment-seeking adults with moderate or severe OUD increases subsequent outpatient treatment engagement as compared to a historical control cohort and concurrent controls who decline treatment participation.
The study will also assess whether rapid initiation of SUBLOCADE® reduces subsequent ED visits for any reason.
As a exploratory aim we will examine whether rapid initiation of Sublocade in this patient group reduces opioid overdose events compared to historical controls and patients who decline Sublocade.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Signed the informed consent form (ICF) and have the ability to comply with the requirements and restrictions listed therein.
- Age: ≥ 18 years at time of executing the ICF.
- Currently meets DSM-5 criteria for moderate to severe OUD.
- Is clinically stable (respiratory rate [RR] ≥ 12, pulse oximetry > 95%, Glasgow Coma Scale [GCS] score of 15) and suitable for the trial in investigator's or designee's judgement.
- Agrees not to take any buprenorphine products other than those administered during the current study throughout participation in the study.
- Negative urine pregnancy test for females.
- Vital signs (BP, HR, temperature) considered within normal limits or non-clinically significant elevation, as assessed by treating physician.
- Provide a urine drug screen positive for illicit opioids, excluding methadone.
- Have a COWS score ≥ 8.
- Is seeking medication-assisted treatment for OUD.
Exclusion Criteria:
- Current diagnosis, other than OUD, requiring chronic opioid treatment.
- Active suicidal ideation in opinion of the Investigator or designee.
- Female subject that is lactating, pregnant or planning to become pregnant during their participation in the study.
- Uncontrolled intercurrent illness including, but not limited to, psychiatric illness that would limit compliance with study requirements or compromise the ability of the subject to provide written informed consent.
- Known allergy or hypersensitivity to SUBOXONE or SUBLOCADE.
- Any condition that, in the opinion of the Investigator would interfere with interpretation of subject safety or study results.
- Currently receiving methadone, depot naltrexone, or Probuphine for OUD or received those treatments for OUD within 30 days prior to consent.
- Current or concurrent treatment with an investigational agent.
- Current or concurrent enrollment in another clinical study, or observational study that includes MAT.
- Treatment for OUD required by court order.
- Current or pending incarceration/legal action that could affect participation or compliance in the study.
- Subjects who are unable, in the opinion of the Investigator, to comply fully with the study requirements.
- Less than 48-72 hours since last use of long acting opioids (i.e., methadone), by self-report.
- Current intoxication with benzodiazepines or alcohol.
- Meet current DSM-5 diagnosis for severe Benzodiazepine or Alcohol Use Disorder or endorse benzodiazepine or alcohol withdrawal symptoms.
- Current illicit opioid users who endorse regular use of long acting opioids (i.e., methadone).
- Total bilirubin ≥ 1.5x the upper limit of normal (ULN), alanine aminotransferase (ALT) ≥3xULN, aspartate aminotransferase (AST) ≥ 3xULN, serum creatinine > 2xULN, international normalized ratio (INR) >1.5xULN. If these results are unable to be obtained prior to enrolling the subject, the investigator can make an initial determination about eligibility based on LFTs collected in the past 6 months from the subject's medical record.
- Patients with a history of Long QT Syndrome or an immediate family member with this condition or those taking Class lA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide) or Class Ill antiarrhythmic medications (e.g., sotalol, amiodarone) or other medications that prolong the QT interval.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Opioid withdrawal patients
Subjects with opioid use disorder seeking treatment and/or experiencing symptoms of opioid withdrawal receive acute administration of SUBOXONE sublingual film followed by SUBLOCADE administration in the 1) ED, 2) Clinical Decision Unit or 3) Inpatient unit combined with 6 months of treatment with SUBLOCADE in the outpatient treatment clinic.
|
SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment engagement - 1 month
Time Frame: 1 month
|
Treatment engagement as measured by percentage of participants who attend an outpatient clinic visit within 1 month of first injection.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment engagement - 3 and 6 months
Time Frame: 3 and 6 months
|
Treatment engagement as measured by percentage of participants who continue to attend outpatient clinic visits with SUBLOCADE injections (buprenorphine treatment) at 3 and 6 months.
|
3 and 6 months
|
Number of repeat ED visits
Time Frame: 6 months
|
Number of repeat ED visits for any reason will be measured from electronic medical records and self-reported data.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healthcare resource utilization
Time Frame: 6 months
|
Healthcare resource utilization (measured by number of outpatient clinic and emergency department visits, and number of inpatient admissions) as compared to the concurrent and historical control groups.
|
6 months
|
Opioid craving
Time Frame: 6 months
|
Opioid craving in subjects as measured by Craving Visual Analog Scale (VAS), a 3-item scale in which individuals rate their cravings for opioids on a scale from 0 (NOT AT ALL) to 10 (EXTREMELY).
|
6 months
|
Number of participants with a urine drug screen negative for illicit opioids.
Time Frame: 6 months
|
Illicit opioid use as measured by urine drug screen (UDS) results.
|
6 months
|
Impulse control
Time Frame: 6 months
|
Time to decision in delay discounting task
|
6 months
|
Opioid cravings
Time Frame: 6 months
|
Brief opioid demand task
|
6 months
|
Number of non-fatal or fatal opioid-related overdoses
Time Frame: 6 months
|
Data on the number of opioid overdoses will be measured from electronic medical records and/or state death registries.
|
6 months
|
Treatment effectiveness: Treatment Effectiveness Assessment (TEA)
Time Frame: 6 months
|
Treatment effectiveness as measured by Treatment Effectiveness Assessment (TEA), which measures on 4 domains (substance use, health, lifestyle, community involvement).
Responses on each item range from 1 ("not better at all") to 10 ("very much better") with items summed for a total score of 4-40, and higher scores reflecting greater self-report of treatment effectiveness.
|
6 months
|
Medication satisfaction: Medication Satisfaction Questionnaire (MSQ)
Time Frame: 6 months
|
Measured by the Medication Satisfaction Questionnaire (MSQ), a single item that asks participants to rate how satisfied they are with their current opioid dependence medication on a scale from 1 ("extremely dissatisfied") to 7 ("extremely satisfied").
Higher scores reflect greater satisfaction with the medication.
|
6 months
|
Employment, presentism and absenteeism
Time Frame: 6 months
|
Assessed by the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP), which measures the effects of opioid use disorder on the ability to work and perform regular activities among participants.
Items evaluate hours of work completed and hours of work missed in the past 7 days and ask participants to rate the impact on their work productivity and regular activities in the past 7 days on a scale of 0 ("problem had no effect on my work/regular activities") to 10 ("problem completely prevented me from working/regular activities"), with higher scores reflecting greater severity and worse outcomes on the measure.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2021
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
December 31, 2021
Study Registration Dates
First Submitted
August 19, 2020
First Submitted That Met QC Criteria
August 21, 2020
First Posted (Actual)
August 24, 2020
Study Record Updates
Last Update Posted (Actual)
February 12, 2021
Last Update Submitted That Met QC Criteria
February 9, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Substance-Related Disorders
- Disease Attributes
- Narcotic-Related Disorders
- Emergencies
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
Other Study ID Numbers
- HM20020289
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
Clinical Trials on SUBLOCADE
-
Indivior Inc.CompletedOpioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
The University of New South WalesUnknown
-
Ohio State UniversityWithdrawnOpioid Use DisorderUnited States
-
Virginia Commonwealth UniversityIndivior, PLC.Terminated
-
New York State Psychiatric InstituteCompletedOpioid-use DisorderUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Withdrawn
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Rhode Island HospitalRecruitingOpioid Use Disorder | Human Immunodeficiency VirusUnited States
-
Indivior Inc.Active, not recruitingModerate to Severe Opioid-use DisorderUnited States, Canada